Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.
mikeelogan

Kim Jong Un Struggles With Rapid Weight Gain - Upi.com

CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia - Yahoo Finance

In 2014 when Kim was absent from public events for 40 days and later reappeared with a cane, some analysts said the injury was the result of gout while others said it was due to a broken ankle, Sky News reported . Pyongyang eventually admitted Kim had suffered from "discomfort" but without providing details. One South Korean doctor said based on Kim's weight it is possible his "cholesterol levels are...off the charts," and that Kim is ailing from "metabolic syndrome, a hodgepodge of pre-diabetes symptoms such as high blood pressure, hyperlipidemia and obesity." Earlier this month Sky News reported Kim appeared on North Korean television with a bandage tied around his right wrist. The bandage was visible as Kim waved and smiled at a gathering during a weapons factory tour in Pyongyang around April 10.
For the original version including any supplementary images or video, visit http://www.upi.com/Top_News/World-News/2015/04/22/Kim-Jong-Uns-weight-gain-places-him-at-risk-of-heart-attack-experts-say/2391429708065/

Amazon http://goutcureguide.info/gout-tips-on-diagnosis-treatment-and-patient-education/ to Carry Complete Natural Products, Available to Millions of Consumers

Food and Drug Administration (FDA) has granted the Company orphan drug designation for MBX-8025 for the treatment of HoFH. MBX-8025 has also received orphan designation for Fredrickson types I and V hyperlipoproteinemia. About MBX-8025 MBX-8025 is a potent and selective agonist of PPAR, a nuclear receptor important for lipid transport, storage and metabolism in liver and muscle.MBX-8025 has shown favorable effects on lipid and metabolic parameters in a Phase 2 study in patients with mixed dyslipidemia.Treatment effects observed include lowering of LDL-C with selective depletion of pro-atherogenic dense LDL-C particles, decreases in triglycerides and increases in high density lipoprotein, as well as decreases in hsCRP, a biomarker of cardiovascular inflammation.CymaBay has initiated a pilot clinical study evaluating the activity of MBX-8025 in patients with homozygous familial hypercholesterolemia.The U.S. Food and Drug Administration (FDA) has granted CymaBay orphan drug designation for MBX-8025 as a treatment for homozygous familial hypercholesterolemia (HoFH) and Fredrickson types I and V hyperlipoproteinemia. About CymaBay CymaBay Therapeutics, Inc. ( CBAY ) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate, the company's lead product candidate, has shown two therapeutic actions in a single drug in multiple Phase 2 gout studies. In gout patients, arhalofenate is intended to prevent company website painful flares in joints while at the same time promoting excretion of uric acid by the kidney, thereby addressing both the signs and symptoms of gout and the hyperuricemia that is the root cause of the disease.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/cymabay-therapeutics-announces-initiation-phase-120000483.html

Lew Fidler Says He Found a Kidney Donor | Observer

Mr. Fidler, a Brooklyn Democrat, had been actively seeking a donor since last September. He said hiskidneys failed following an allergic reaction to a prescribed medicine to control his gout. GREAT NEWS! I AM GETTING A KIDNEY! Surgery set for May 21st! I am grateful, ecstaticand a bit nervous, Mr. Fidler, 58, wrote on Facebook.
For the original version including any supplementary images or video, visit http://observer.com/2015/04/former-city-councilman-announces-he-has-found-kidney-donor/

The results are highly effective supplements that leverage the power of multiple ingredients to help people dealing with conditions affecting the kidneys, liver, prostate, urinary tract, joints, gallbladder and more. We are thrilled to announce that our supplements are now available on Amazon, a go-to source for health and nutrition products for consumers across the United States and beyond, said Scot Poole, owner of Complete Natural Products. We look forward to the impact our products will have on this platform, as there is now the potential for millions of more individuals to discover just how effective and helpful our products can be. This is great news for our brand as we continue to expand our line throughout the U.S. market. Through its formulas, the Complete Natural Products line targets the root causes and symptoms of common health issues like arthritis, liver problems, urinary tract infections, gout, gallbladder conditions, acid reflux and a variety of others. Its ingredients are carefully selected for quality and the right potencies that will result in optimal effectiveness for consumers.
For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/04/prweb12674365.htm

CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia - Yahoo Finance

A new study, led by WVU psychology professor Steven Kinsey, combines existing over the counter medicines (such as Aleve and Tylenol) and experimental drugs in smaller doses to see if they work better together than either drug alone. We want to provide better mobility than other existing pain medicines offer, Kinsey said. We want to reduce pain, but more than that, we want to restore peoples function. West Virginia University has been awarded $395,120 from the National Institutes of Health to help find new methods of relief for an affliction that is the leading cause of disability in the United States. So far, Kinsey said, promising laboratory work with mouse subjects has shown that the mice have increased mobility after receiving the new drugs treatments. Improving the quality of life for arthritis sufferers is a cause that unexpectedly hit close to home for Kinsey. The disease is so commonplace that its often brushed aside, Kinsey said, despite so many people suffering or not knowing they suffer from it.
For the original version including any supplementary images or video, visit http://www.newswise.com/articles/view/633092/?sc=rsmn

New WVU Study Combines Arthritis Meds to Better Alleviate Pain

Orphan drug designation was created to encourage the development of products that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. Among other benefits, the designation potentially qualifies the sponsor for seven years marketing exclusivity period upon approval, as well as exemption from FDA application fees, and tax credits for qualified clinical trials. "This second orphan drug designation is a validation of the company's development strategy for MBX-8025 in which we are targeting indications with high unmet need and potentially expedited approval pathways," said Harold Van Wart, President and Chief Executive Officer of CymaBay."MBX-8025 potentially offers unique benefits for the treatment of metabolic disorders including HoFH, severe hypertriglyceridemia, primary biliary cirrhosis and nonalcoholic steatohepatitis.We remain on track to initiate a Phase 2 pilot study of MBX-8025 in HoFH this quarter, and look forward to announcing further details regarding the expansion of our development strategy of MBX-8025 in the near-term." Patients with types I and V hyperlipoproteinemias have severely elevated levels of triglycerides in the blood.Type I is characterized by deficiencies related to lipoprotein lipase (LPL) and by an elevation of chylomicron particles. Type V is characterized by an elevation in very-low-density lipoprotein (VLDL). Both types of hyperlipoproteinia are associated with an increased risk of acute and chronic pancreatitis that is severe and potentially life-threatening.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/cymabay-therapeutics-announces-u-orphan-120000421.html

Don't be the product, buy the product!

Schweinderl